JP2017529332A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529332A5
JP2017529332A5 JP2017511200A JP2017511200A JP2017529332A5 JP 2017529332 A5 JP2017529332 A5 JP 2017529332A5 JP 2017511200 A JP2017511200 A JP 2017511200A JP 2017511200 A JP2017511200 A JP 2017511200A JP 2017529332 A5 JP2017529332 A5 JP 2017529332A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
thieno
triazolo
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017511200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/069754 external-priority patent/WO2016030509A1/en
Publication of JP2017529332A publication Critical patent/JP2017529332A/ja
Publication of JP2017529332A5 publication Critical patent/JP2017529332A5/ja
Withdrawn legal-status Critical Current

Links

JP2017511200A 2014-08-28 2015-08-28 チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法 Withdrawn JP2017529332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043063P 2014-08-28 2014-08-28
US62/043,063 2014-08-28
PCT/EP2015/069754 WO2016030509A1 (en) 2014-08-28 2015-08-28 Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds

Publications (2)

Publication Number Publication Date
JP2017529332A JP2017529332A (ja) 2017-10-05
JP2017529332A5 true JP2017529332A5 (enExample) 2018-10-11

Family

ID=54012215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511200A Withdrawn JP2017529332A (ja) 2014-08-28 2015-08-28 チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法

Country Status (6)

Country Link
US (1) US20170281642A1 (enExample)
EP (1) EP3185871A1 (enExample)
JP (1) JP2017529332A (enExample)
KR (1) KR20170044172A (enExample)
CN (1) CN107427524A (enExample)
WO (1) WO2016030509A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160145833A (ko) * 2014-05-02 2016-12-20 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
US10159660B2 (en) * 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
KR102325607B1 (ko) * 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
BR112022018553A2 (pt) * 2020-03-18 2022-11-29 Metacrine Inc Formulações de um agonista do receptor x farnesoide
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
US20240190849A1 (en) 2021-02-26 2024-06-13 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
CA3260633A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CA3259217A1 (en) 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2025129014A1 (en) 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2026035809A1 (en) 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412776C (en) * 2000-06-16 2011-03-15 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
MX373121B (es) * 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
MX384074B (es) * 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
MX2015003771A (es) * 2012-09-28 2016-03-04 Oncoethix Gmbh Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina.
CN106029077A (zh) * 2013-08-01 2016-10-12 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法

Similar Documents

Publication Publication Date Title
JP2017519727A5 (enExample)
JP2012136540A5 (enExample)
JP2017527578A5 (enExample)
JP2018168191A5 (enExample)
JP2015511638A5 (enExample)
JP2016529246A5 (enExample)
JP2016538310A5 (enExample)
JP2017519027A5 (enExample)
JP2015534578A5 (enExample)
JP2012507538A5 (enExample)
JP2016503010A5 (enExample)
JP2014518544A5 (enExample)
JP2010529118A5 (enExample)
JP2013237682A5 (enExample)
JP2014518266A5 (enExample)
JP2015515475A5 (enExample)
HRP20231533T1 (hr) Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave
JP2016540021A5 (enExample)
JP2014508752A5 (enExample)
JP2015523407A5 (enExample)
JP2015504091A5 (enExample)
WO2017044792A8 (en) Acetamide thienotriazolodiazepines and uses thereof
JP2019505529A5 (enExample)
JP2013209384A5 (enExample)
JP2019520344A5 (enExample)